Changes in Beneficial Ownership · 4
Whitehawk Therapeutics, Inc.
WHWKNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06152026_090621.xml
Filing details
- Report period
- 2026-06-12
- Issuer
- Whitehawk Therapeutics, Inc.
- Issuer CIK
- 0001422142
- Trading symbol
- WHWK
Reporting owner 1
- Name
- Castelein Caley
- Reporting owner CIK
- 0001355758
- Relationship
- Director
- Address
- C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T, MORRISTOWN, NJ, 07960
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 4.16 | 2026-06-12 | A · Form 4 | 38,040 | A | 0 | [F1] | 2036-06-12 | Common Stock | 38,040 | 38,040 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.↩ 1
Signature 1
- Signed
- /s/ Stephen Rodin, as Attorney-in-Fact
- Date
- 2026-06-15
Company context
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk’s portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 10, 2026
- SCHEDULE 13G/A - filed by ABG Management Ltd. regarding Whitehawk Therapeutics, Inc.Aug 14, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial ConditionAug 6, 2026
- 4 filingJun 15, 2026